Medicenna Reports Strong MDNA11 Data, Advances Pipeline with IND Plans for MDNA113
Event summary
- MDNA11 achieved a 36% ORR in monotherapy and 43% ORR in combination with pembrolizumab in earlier-line expansion cohorts.
- NEO-CYT trial for melanoma to begin enrollment in H1 2026, with interim data expected in H2 2026.
- MDNA113 shows favorable safety profile in non-human primates, IND submission planned for H2 2026.
- Bizaxofusp data to be presented at the Glioblastoma Development Summit on February 19, 2026.
The big picture
Medicenna's updated clinical data for MDNA11 positions it as a potential best-in-class therapy for solid tumors following checkpoint resistance. The advancement of MDNA113 towards IND submission and the strategic focus on high-impact opportunities reflect the company's commitment to improving cancer treatment standards. The upcoming presentation on bizaxofusp at the Glioblastoma Development Summit could attract potential partners for the program's commercialization.
What we're watching
- Clinical Efficacy
- Whether MDNA11's strong ORR in earlier-line expansion cohorts can translate into long-term survival benefits and regulatory approval.
- Regulatory Pathway
- The pace at which Medicenna advances MDNA113 towards IND submission and potential registrational trials.
- Financial Runway
- How Medicenna manages its cash runway into Q3 2026 while advancing multiple clinical programs.
Related topics